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SUMMARY 61 
The human intestinal ecosystem is characterized by a complex interplay between different 62 
microorganisms and the host. The high variation within the human population further complicates 63 
the quest towards adequate understanding of this complex system that is so relevant to human 64 
health and well-being. To study host-microbe interactions, defined synthetic bacterial communities 65 
have been introduced in gnotobiotic animals or in sophisticated in vitro cell models. This review 66 
reinforces that our limited understanding has often hampered appropriate design of defined 67 
communities that represent the human gut microbiota. On top of this, some communities have been 68 
applied to in vivo models that differ appreciably from the human host. In this review, the advantages 69 
and disadvantages of using defined microbial communities are outlined, and suggestions for future 70 
improvement of host-microbe interaction models are provided. With respect to the host, 71 
technological advances, such as the development of a gut-on-a-chip and intestinal organoids, may 72 
contribute to more accurate in vitro models of the human host. With respect to the microbiota, due 73 
to increasing availability of representative cultured isolates and their genomic sequences, our 74 
understanding and controllability of the human gut ‘core microbiota’ is likely to increase. Taken 75 
together, these advancements could further unravel the molecular mechanisms underlying the 76 
human-gut microbiota superorganism. Such a gain of insight would provide a solid basis for the 77 
improvement of pre-, pro- and synbiotics as well as the development of new therapeutic microbes.   78 
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INTRODUCTION 79 
Given its involvement in metabolic, nutritional, physiological and immunological processes, the 80 
human intestinal microbiome can be regarded as an essential organ of the human body (1). Further 81 
strengthening its clinical relevance, the intestinal microbiome has been linked to numerous disease 82 
conditions, including metabolic and immune disorders, cancer and neurodegenerative diseases (2). 83 
Apart from a remarkable increase in genome sequence data of the human gut microbiota, however, 84 
progress in functional insight has been hampered by its complexity: the existence of more than 85 
1,000 prevalent species (3) combined with the high interpersonal variation within the human 86 
population in terms of genetics, environment and habits, results in a complex entity termed the 87 
human-microbiome superorganism (4). The number of known host-microbe interactions has grown 88 
rapidly over the past decades, yet many aspects still remain obscure.  89 
To solve this complexity, there is need for a reductionist approach in which both host and 90 
microbiome are simplified to the extent that experimental variables can be tightly controlled and 91 
deliberately manipulated. Regarding the microbiota, synthetic or defined communities have been 92 
proposed as useful models to study microbial ecology (5). In recent years, the number of cultivable 93 
gastrointestinal microbial species has rapidly expanded (3) by the use of sophisticated or brute 94 
force culturomics approaches (6, 7). These strategies have allowed for the design of defined 95 
communities that are representative of the normal human intestinal microbiota. With respect to the 96 
human host, laboratory animals, notably mice, have proven valuable models for developing human 97 
medicine. The colonization of germ-free (GF) animals with defined bacterial communities, 98 
resulting in gnotobiotic animals, has already been applied for decades. During the 1960s and 1970s, 99 
it was recognized that the intestines of GF animals display aberrant histological, anatomical and 100 
physiological characteristics compared to conventional laboratory animals (8). The development 101 
6 
 
of the Schaedler cocktail for colonization of the murine gut (9) marked one of the first attempts to 102 
normalize GF mice. An altered version has been widely adopted as a standardised gut microbiota 103 
by animal breeders and biomedical researchers ever since. Over time, various other defined 104 
communities have been designed to generate gnotobiotic animals for purposes beyond 105 
standardisation; they have proven a valuable in vivo tool to study microbial ecology (e.g. microbial 106 
invasion, microbe-microbe interactions, and metabolism) and host-microbe interactions. However, 107 
mice and other animal models have various limitations that hamper their use as models for the 108 
human microbiome, as has been recently reviewed (10, 11). Interesting alternatives concern the 109 
development of sophisticated in vitro models, such as organ-on-chip systems and organoids. 110 
 This review summarizes existing models of host-microbe interactions in which defined 111 
communities, as models of the (human) gut microbiota, were applied. We aim to present all in vivo 112 
studies that used defined microbial communities representing the intestinal microbiota of healthy 113 
individuals and in which host parameters were considered. The design of these model communities, 114 
as well as the selection of its host, are compared and critically evaluated. The potential use of 115 
defined communities in in vitro (cellular) models, as a surrogate host, are outlined as well. We 116 
conclude by discussing the increased value, opportunities and possible obstacles when applying 117 
defined communities in to-be-developed in vitro host-microbe interaction models.  118 
119 
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MAIN TEXT 120 
Defined Communities Mimicking the Normal Intestinal Microbiota In Vivo 121 
A number of recent studies addressed host-microbe interactions in vivo by using defined 122 
communities representative of the healthy human gut microbiota (Table 1a-c). These include 123 
various mouse studies with more or less defined intestinal microbiota that are summarized below. 124 
Studies in which animals were antibiotic-treated before bacterial colonization are excluded from 125 
our analysis as their reproducibility and gnotobiology cannot be reassured (12). The following 126 
section first discusses the specifically named defined communities applied in rodents (Table 1a, n 127 
= 31), followed by non-specifically named communities in rodents (Table 1b, n = 16). Finally, the 128 
defined communities administered to non-rodent models are discussed (Table 1c, n = 6). 129 
(Altered) Schaedler flora 130 
In 1965, Russel W. Schaedler colonized GF mice with a defined microbial community composed 131 
of strains isolated from normal mice, to study the fate of the bacteria in the gastrointestinal tract 132 
(GIT) and their effect on caecum size. With respect to these parameters, it turned out that the 133 
Schaedler flora (SF) was able to, at least partially, normalize the caecum size of the GF size in 134 
comparison with animals raised under conventional conditions (9). The defined microbial 135 
population was supplied to animal vendors to serve as a community that could limit the infection 136 
of ex-GF rodents with opportunistic pathogens. Schaedler developed several different bacterial 137 
cocktails over time. In 1978, Roger P. Orcutt set out to standardize and improve the SF flora, but 138 
in view of the monitoring costs, the total number of bacterial species was limited to eight. Orcutt 139 
made a selection of bacterial species (Altered Schaedler Flora (ASF)) based on their representation 140 
and stable colonization in the murine gut, their ease of identification (morphologically) and their 141 
presence in or interference with isolator contaminants. For instance, the cocci and spore-forming, 142 
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blunt-ended rods were eliminated, which represented the majority of isolator contaminants. Also, 143 
the amount of facultative anaerobes was limited, as they outgrew aerobic isolator contaminants and 144 
thus, impeded the ability to detect the latter (13). The ASF consists of six Firmicutes (Clostridium 145 
species (ASF356), Lactobacillus intestinalis or acidophilus (ASF360), Lactobacillus murinus or 146 
salivarius (ASF361), Eubacterium plexicaudatum (ASF492), Pseudoflavonifractor sp. (ASF500) 147 
and Clostridium sp. (ASF502)), one Bacteroidetes (Parabacteroides distasonis (ASF519)) and one 148 
Deferribacteres (Mucispirillum schaedleri (ASF457)).  149 
The ASF has been used multiple times as a reference or minimal defined microbiota, and its 150 
applications were extensively reviewed elsewhere (14). Several studies involving ASF in mice (or 151 
other animals) reported its effect on host parameters (Table 1a-c). The list is probably not 152 
exhaustive, given the wide application of ASF mice as control or minor population in studies, 153 
which makes these studies harder to identify.  154 
 The applications of ASF in rodents varied from wild-type strains (mostly C57BL/6, but also 155 
C3H/HeN and Swiss-Webster mice) to models prone to diseases including IBD (15-17), type I 156 
diabetes (18) or colorectal cancer (19). The ASF lacks Proteobacteria, a phylum shared by mice 157 
and humans, whereas some researchers did introduce Proteobacteria to ASF mice, such as 158 
Oxalobacter formigenes (20) and Escherichia coli (21). Other studies included only selected 159 
members of the ASF, because not all were found to successfully colonize the murine caecum (18) 160 
or to test the level of colonization resistance of different combinations of ASF members (22). 161 
Overall, the application of ASF to study host-microbe interactions has been quite diverse, regarding 162 
host strain, gut region of interest and host parameters studied.  163 
Although the ASF has been used multiple times as a reference microbiota and has aided in the 164 
establishment of other defined microbiota, such as Oligo-MM and the Bristol Microbiota, its 165 
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representability of the normal gut microbiota has been criticized (23), as discussed later in this 166 
review. 167 
Oligo-MM 168 
Another defined community of murine microbiota, Oligo-MM12, was constructed in an attempt to 169 
provide full colonization resistance against Salmonella enterica serovar Typhimurium (S. Tm) 170 
(22). Twelve strains were selected to represent the five most prevalent and abundant phyla of the 171 
laboratory mouse intestine, i.e. Firmicutes: ‘Acutalibacter muris’, Flavonifractor plautii, 172 
Clostridium clostridioforme, Blautia coccoides, Clostridium innocuum, Lactobacillus reuteri, 173 
Enterococcus faecalis; Bacteroidetes: ‘Bacteroides caecimuris’, ‘Muribaculum intestinale’; 174 
Actinobacteria: Bifidobacterium longum subsp. animalis; Proteobacteria: ‘Turicimonas muris’ and 175 
Verrucomicrobia: Akkermansia muciniphila. Colonization resistance of ASF mice or mice 176 
colonized with Oligo-MM12 and/or (a subset of) ASF strains, were compared to conventional mice. 177 
ASF was used as a reference, because of its wide usage in gnotobiotic mouse research. Oligo-MM12 178 
mice conferred increased, but not full, resistance compared to mice colonized with a subset of ASF 179 
strains with and without Oligo-MM. Functional genomic analysis of Oligo-MM and whole ASF 180 
revealed that both consortia together cover 66.6% of the KEGG modules of a conventional mouse 181 
microbiota. Addition of three facultative anaerobes (E. coli, Streptococcus danieliae and 182 
Staphylococcus xylosus), underrepresented in Oligo-MM12, increased coverage and furthermore, 183 
conferred full colonization resistance (22). C57Bl/6 mice stably colonized with Oligo-MM12 have 184 
been designated stable Defined Moderately Diverse Microbiota mice (sDMDMm2). The designers 185 
of Oligo-MM12 stressed the importance of expanding the amount of available mouse-derived 186 
strains, as initiated recently (24), in favour of the design of functionally defined and simplified 187 
microbial consortia for application in gnotobiotic animals (22). Because Oligo-MM12 found to lack 188 
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the enzymatic pathway to carry out 7α-dehydroxylation, an important bile acid transformation, the 189 
addition of Clostridium scindens (a 7α-dehydroxylating bacterium) was tested in another study. 190 
This modification normalized large intestinal bile acid composition in mice, which was 191 
accompanied by colonization resistance against Clostridium difficile and decreased intestinal 192 
pathology (25). Finally, Oligo-MM12 served as a defined reference microbiota to verify the 193 
significant difference between the bacterial composition in the large intestinal outer mucus layer 194 
and the lumen (26), but host parameters were not assessed. Note that the latter two studies that 195 
applied of Oligo-MM12 left out the three additional facultative anaerobes that were found to be 196 
crucial for full colonization resistance. 197 
SIHUMI(x) 198 
Because ASF was found to poorly represent the dominant intestinal bacteria and ASF mice hardly 199 
differed from GF mice in a key set of microbial biochemical activities (23) (Midtvedt criteria, see 200 
below), a simplified human intestinal microbiota (SIHUMI) was established in rats to provide a 201 
highly standardized animal model to study host-microbe interactions. Species were selected 202 
according to their prevalence in humans, their fermentative capacity, the availability of their 203 
genomic sequence and their ability to stably colonize the rodent gut. SIHUMI(x) includes four 204 
Firmicutes (Anaerostipes caccae), Lactobacillus plantarum, Blautia producta and Clostridium 205 
ramosum), one Bacteroidetes (Bacteroides thetaiotaomicron), one Actinobacterium (B. longum) 206 
and one proteobacterium (E. coli). All seven members successfully colonized the rat intestinal tract 207 
and total bacterial numbers in faecal samples did not differ from those in human faeces. The amount 208 
of short-chain fatty acids (SCFAs) produced, however, was dramatically lower compared to 209 
humans, probably owing to the smaller number of species. An eighth species was added to the 210 
consortium (SIHUMIx), Clostridium butyricum, which led to increased butyrate production. All 211 
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members of the SIHUMIx were successfully transferred to offspring. Dietary interventions varying 212 
in fibre and fat content resulted in responses (partially) reflecting those observed in mice and 213 
humans (27).  214 
In other studies, SIHUMIx served as a resident community to study the effect of the addition or 215 
removal of species. For instance, inclusion of A. muciniphila, a mucin-degrading commensal, was 216 
found to worsen intestinal inflammation induced by S. typhimurium Tm in mice (28). The same 217 
researchers recently showed, however, that in a colitis-prone mouse model colonized with 218 
SIHUMI, A. muciniphila did not induce or exacerbate intestinal inflammation (29). In two other 219 
studies, the polyamine-producing Fusobacterium varium was added to the low polyamine-220 
producing SIHUMIx in mice, which disclosed that gut morphology was neither affected by 221 
increased putrescine concentrations (30), nor by higher levels of other polyamines and SCFAs (31). 222 
Additionally, the mechanism underlying the obesogenic potential of C. ramosum in a SIHUMIx-223 
associated animal model was further investigated by including or excluding this bacterium in 224 
SIHUMIx-associated mice fed a high- or a low-fat diet. The increased body fat deposition in the 225 
presence of C. ramosum was suggested to be due to the upregulation of small intestinal glucose 226 
and fat transporters (32). It should be noted that, although SIHUMI was originally established in 227 
rats, all other studies applied the community in mice. 228 
Towards a normal model gut microbiota 229 
Since the generation of the Schaedler flora in the 1960s, other defined gut microbiotas have been 230 
developed in an attempt to normalize GF animals or generate animal models harbouring a bacterial 231 
community representative of the human gut microbiome. During the 1970s, Syed et al. aimed to 232 
normalize GF mice with respect to caecum size, caecal numbers of E. coli, histology of the 233 
intestinal tract, and the development of a mucosa-associated microbiota in stomach and large 234 
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intestine (33). A mixture of 50 strictly anaerobic (later designated ‘N-strains’ (34)) and 70 235 
facultative anaerobes (‘F-strains’) were found to generate a normal mouse phenotype, whereas less 236 
complex bacterial communities led to intermediate phenotypes with respect to the parameters 237 
studied, including caecum size, caecal E. coli levels, GIT histology and development of a mucosa-238 
associated microbiota in stomach and large intestine (33). The exact taxonomic classification of 239 
the species within the F- and N-strains was limited by lack of characterization at that time (33). It 240 
was considered likely that a number of the isolates used were identical. Based on morphology and 241 
fatty acid production, the total of number of different strains was estimated to be rather in the order 242 
of 35 (N-strains) and 60 (F-strains) (34). The N-strains alone could not control the E. coli 243 
population and caecum size when associated with mice fed on a crude instead of refined diet, but 244 
this could be restored by additional association with the F-strains (34). The F-strains were exploited 245 
as an indigenous gut microbiota to investigate E. coli plasmid transfer in vivo (35), but other studies 246 
using the N- or F-strains could not be identified.  247 
 At the end of the 1970s, the use of the UW-GL (University of Wisconsin Gnotobiote 248 
Laboratory) flora was reported, which was used as the intestinal microbiota of heterozygous 249 
athymic mice (36). This defined bacteriome consisted of nine Gram-positive species from the 250 
genera Lactobacillus, Bacillus, Clostridium and Corynebacterium (37) and additionally, two 251 
Gram-negative species that were not further specified (36). It was used to study its colonization 252 
resistance against Candida albicans (37) and Clostridium botulinum (36). The latter study 253 
compared UW-GL with other defined microbiotas including ASF and a partial UW-GL. Whereas 254 
death rates significantly dropped compared to GF mice, only complete UW-GL fully prevented C. 255 
botulinum infection (36). The use of the UW-GL microbiota has not been reported since. 256 
 Logically, the conception of a healthy or ‘normal’ microbiota is dependent on the available 257 
knowledge on conventional animals and/or healthy human subjects, and thus the composition 258 
13 
 
varied per study. While testing the effect of bacterial species on intestinal IgA immune system 259 
development, Moreau et al. paid specific attention to communities of Clostridium species, which 260 
was considered a dominant microbiota of the digestive tract of adult conventional mice (38). In 261 
studies using defined communities with human-derived gut bacteria, species were selected based 262 
on their prevalence in (healthy) human faeces (39, 40) and/or their representation of the major three 263 
or four dominant phyla of the human gut microbiota (40-42). Next to the designers of Oligo-MM12, 264 
only few studies acknowledged the presence of five phyla (including Verrucomicrobia) of the 265 
human gut microbiota. A recently designed 14-membered synthetic microbiota that collectively 266 
possessed important core metabolic capabilities was applied to study in vivo foraging of host-267 
derived mucus glycoproteins during fibre deprivation (43). Similarly, other studies took into 268 
account the functional capabilities of species. For instance, one study included species that are able 269 
to break down complex dietary polysaccharides not accessible to the host (B. thetaiotaomicron, 270 
Bacteroides ovatus, Bacteroides caccae), to consume oligosaccharides and simple sugars 271 
(Eubacterium rectale, Marvinbryantia formatexigens, Collinsella aerofaciens and E. coli), to 272 
ferment amino acids (Clostridium symbiosum and E. coli) or to remove the end products of 273 
fermentation by reducing sulfate (Desulfovibrio piger) or generate acetate (Blautia 274 
hydrogenotrophica) (41). This community has been frequently exploited to study host-microbe 275 
interactions or microbe-microbe interactions by the same research group or adopted by others, 276 
albeit in different combinations ranging from eight to 15 species (40, 42, 44-50). Recently, a more 277 
diverse, complex defined community comprising not less than 92 species was developed (51). The 278 
consortium consisted of phylogenetically diverse, human-derived bacterial strains, which had 279 
previously been cultured and sequenced. It also included strains representing species that were 280 
demonstrated to be age- and/or growth-discriminatory in models of microbiota development during 281 
the first years of life. Of all strains, 44 comprised a core group that could be detected in faecal 282 
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samples of all colonized mice, independent of dietary intervention (51). No host parameters, 283 
however, were assessed in this study.  284 
 Remaining inclusion criteria for defined communities are the availability of the genomic 285 
sequence and the cultivability of the species. Obviously, both criteria make each individual species 286 
more easily traceable. If the entire genetic repertoire of the defined community is known, gene 287 
expression of the whole community as well as its individual members can easily be assessed (28, 288 
40) and their function can be more precisely predicted. Interestingly, although ASF has been used 289 
for over 50 years, publications on replication of the four extremely-oxygen sensitive ASF members 290 
on a defined medium, is still lacking (14). 291 
Defined communities in non-rodents 292 
Previously discussed defined microbiota were either isolated from rodents or applied to them. 293 
Laycock et al. stressed the need for a well-established intestinal colonization microbiota for pigs, 294 
given the higher representability of these animal models in early immune development studies (52): 295 
in pigs, there is no transfer of maternal immunoglobulin G in utero (53, 54), and a poorly developed 296 
mucosal system in neonates (55). Furthermore, pigs are genetically more similar to humans than 297 
mice (56), and their digestive physiology is comparable to ours (57). Colonization of germ-free 298 
piglets with ASF members turned out to be largely unsuccessful and only the most consistently 299 
colonizing ASF member (Parabacteroides sp.) was incorporated in the novel ‘Bristol’ microbiota. 300 
Additional strains were selected based on their representation of the major phylogenetic groups in 301 
gut sections of 12-18 week-old pigs, and either their ability to grow on a wide range of metabolic 302 
carbohydrate structures (Roseburia intestinalis) or their presence in unweaned pigs (Clostridium 303 
glycolicum and Lactobacillus amylovorus). Except for R. intestinalis, the novel microbiota 304 
successfully colonized the GIT after administration to germ-free piglets, with high clinical safety 305 
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and an expected increase in immunoglobulin serum levels (52). The Bristol microbiota was 306 
exploited by other researchers as a simplified starter microbiota to study additional effects of a 307 
complex microbiota on early life microbiota development (58), the intestinal expression of a 308 
butyrate-sensing olfactory receptor (59) and on the gastric transcriptome (60). Note that in the latter 309 
three studies, the piglets were not maintained in a sterile environment, hampering comparison of 310 
the effect of the Bristol microbiota on host parameters between studies. A different ten-membered 311 
porcine gut microbiota, originally designed as a competitive exclusion culture for pigs, was used 312 
to investigate antibody repertoire development in ex-germ-free newborn piglets (61). Another 313 
‘defined commensal microflora’ (DMF) included seven porcine bacterial species and was similar 314 
in composition to ASF. Species were originally isolated from the caecal contents of six week-old 315 
healthy pigs and administered to germ-free pigs to evaluate the interactions between intestinal 316 
commensals, antibiotics, probiotics and human rotavirus. This model was primarily applied as a 317 
model commensal gut microbiota of neonates (62, 63). 318 
Other Defined Communities In Vivo 319 
Apart from the defined communities as model for the normal (human) gut microbiome to study 320 
host-microbe interactions, other kinds of communities have been composed for application in 321 
gnotobiotic animals. These communities, however, are not listed in Table 1a-c and their application 322 
goes beyond the scope of this review, as they did not aim to represent the ‘normal’ microbiota. For 323 
instance, these include disease-specific consortia, e.g. IBD-related (15, 64-67). Others are age-324 
specific, such as the Human Baby Microbiota (68-70), DMF (62, 63) and a recently developed 325 
Bifidum-dominated model consortium (71). Lastly, some communities were developed for 326 
therapeutic or probiotic purposes. A well-studied and globally marketed multispecies probiotic is 327 
the bacterial cocktail VSL#3, which was recently characterized at the genomic level and has been 328 
16 
 
used to treat various gastro-intestinal disorders (72-74). Other communities were designed to treat 329 
infections (amongst others, C. difficile infection (CDI) (75-77) and colitis (78)), or to facilitate 330 
recovery of cholera (79). Two remarkable applications of defined communities, which were not 331 
per se meant to model the normal human gut microbiota, are discussed in more detail below. 332 
Therapeutic communities 333 
Although the concept is not new and pioneered already 30 years ago (75), the interest in faecal 334 
transplantations has recently increased and the avenue of synthetic microbiotas as stool substitutes 335 
has been suggested (80). A particular example of such a stool substitute is Microbial Ecosystem 336 
Therapeutic 1 (MET-1), designed as a synthetic stool mixture to treat recurrent CDI. Sixty-two 337 
species were recovered from the stool of a healthy 41-year-old female donor, of which 33 species 338 
were selected that were sensitive to a range of antimicrobials and were easy to culture. Two CDI 339 
patients that were ‘rePOOPulated’ with MET-1 returned to their normal bowel pattern within a few 340 
days and remained symptom-free for at least six months. The use of a synthetic stool mixture has 341 
several advantages over conventional stool transplants: (i) the bacterial composition is known, 342 
controllable and reproducible, (ii) a pure consortium is more stable than stool, (iii) the formulation 343 
is safe, owing to the lack of viruses and pathogens, and (iv) the administered organisms can be 344 
selected based on their sensitivity to antimicrobials, which further enhances safety (77). Some of 345 
these benefits also strengthen the use of defined communities in host-microbe interaction research. 346 
Notably, the application of MET-1 as a defined community in GF animals, instead of antibiotic-347 
treated animals, was limited to one study, in which it was used as a healthy, Firmicutes-rich 348 
microbiota to study colitis susceptibility and host immune responses (81).  349 
 In contrast to the use of a defined synthetic community, the anaerobically cultivated human 350 
intestinal microflora (ACHIM) has been derived from a fecal sample from a healthy Western donor 351 
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that has been maintained in anaerobic cultured for more than 20 years now and has been applied in 352 
faecal microbiota transplantation (82). Although the microbiota is regularly checked for the 353 
absence of pathogenic organisms and multiple CDI patients have been treated successfully with 354 
this cultured microbiota transplant from a single donor (82), its composition is not controllable. 355 
 Instead of starting with a certain disease or phenotype and generating a defined community 356 
to treat this condition, as true for MET-1 and ACHIM, researchers recently tested different defined 357 
bacterial communities to generate various phenotypes in mice and to identify the strains responsible 358 
for the observed phenotypic variation. By administering GF mice with one of 94 different, defined 359 
bacterial consortia of species randomly drawn from the culture collection, strains were identified 360 
that modulated adiposity, intestinal metabolite composition and the immune system. According to 361 
the authors, a similar approach could be applied to identify and characterize next-generation 362 
probiotics or combinations of pre- and probiotics (83). 363 
Minimal communities 364 
 Another category of defined communities is formed by minimal communities. Essentially, 365 
all defined microbial communities are minimal in the sense that they are not as complex as 366 
microbiota in vivo. Nonetheless, some studies exploited even more simplified defined consortia, 367 
i.e. with a limited amount of species or clearly lacking certain functions, to study host-microbe 368 
interactions in general. This is exemplified by bi-association studies involving single members of 369 
(dominant) phyla. In a recent study GF mice were colonized with B. thetaiotaomicron, as a 370 
prominent member of the adult human gut microbiota, plus one of three probiotic strains (B. 371 
longum, B. animalis or Lactobacillus casei) to study microbe-microbe and host-microbe 372 
interactions (84). In the same lab, gnotobiotic mice were colonized with bacteria from the two 373 
dominant phyla in the adult human distal gut microbiota – Firmicutes and Bacteroidetes. Based on 374 
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their prominence in culture-independent surveys in the distal human gut, the pattern of 375 
representation of carbohydrate active enzymes in their glycobiomes and E. rectale’s ability to 376 
generate butyrate as a major end product of fermentation, a ‘marriage was arranged’ between E. 377 
rectale and B. thetaiotaomicron. This reductionist approach provided information on microbe-378 
microbe interactions, the microbial response to host diet and the microbial effects on host 379 
physiology (e.g. the upregulation of production of (mucin) glycans by the host) (85).  380 
Despite the value of minimal communities for studying microbe-microbe and host-microbe 381 
interactions, a study into mice colonized with another simplified microbiota (B. thetaiotaomicron 382 
and B. longum) clearly demonstrated that the simple microbiota could not reconstitute the 383 
metabolomic complexity of a humanized microbiota, i.e. derived from human donors (86). 384 
Nevertheless, Table 1b-c includes some minimal communities, because of their representation of 385 
major phyla of the human gut microbiota or relevant application to study host parameters. 386 
Critical Evaluation of Defined Communities In Vivo: The Microbiota 387 
In the preceding sections, we provided an objective description of defined microbial communities 388 
that have been applied in in vivo models to study host-microbe interactions. The next section 389 
discusses the representability of these communities, focussing on their design criteria and source 390 
(murine vs. human). Additionally, a comparison is made between simple versus complex, and 391 
bottom-up versus top-down constructed communities. Suggestions for future design of defined 392 
communities representing the normal intestinal microbiota are provided as well.  393 
How representative are defined microbiota models of a normal microbiota? 394 
The development of defined communities representative of the human gut microbiota raises the 395 
issue: “What defines a normal microbiota?”. Among the included studies that aimed to design a 396 
representative gut microbiota, different selection criteria were used. The representation of the major 397 
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phyla and various metabolic capacities have been frequently put forward. A meta-analysis was 398 
performed comparing the composition of the core mouse gut microbiome (based on five different 399 
mouse models, i.e. varying in age, phenotype and sampling site) with the human gut microbiome 400 
(based on 16 individuals) (87). Apart from the differences within the mouse microbiota, 401 
Bacteroidetes and Firmicutes were clearly the most dominant phyla in all samples (together 87-402 
97%). (87) The same is true for the composition of well-established defined communities ASF, 403 
SIHUMI(x) and Oligo-MM12 (75-87.5%). Similar to most murine microbiota included in the meta-404 
analysis, however, ASF and SIHUMI(x) lack Verrucomicrobia, which was found among the five 405 
most abundant phyla in human and some murine samples (87). In that sense, Oligo-MM12, 406 
originally designed to represent the murine microbiota, is compositionally more complete than 407 
SIHUMI(x), which was meant to represent the human microbiota. The frequently used ASF also 408 
lacks Actinobacteria and Proteobacteria, which are abundant in both murine and human samples 409 
(87-89). Similarly, a large part of the other defined communities discussed here (Table 1a-c) did 410 
not include representatives of all five major phyla of the human microbiota, some not even one of 411 
the two most prominent phyla. Note that species selection has been mostly based on microbiota 412 
composition of Western individuals.  413 
Further, community design has been limited by availability of genomes and cultivability of strains. 414 
In the case of ASF, the number of species was limited for financial reasons, i.e. taking into account 415 
the monitoring costs. Nevertheless, this community has been frequently used in gnotobiotic animal 416 
models. The assumption that ASF mice can be regarded as conventional mice with respect to their 417 
gut microbiota, has been criticized (23). Several functional activities in faecal materials from ASF 418 
mice were analysed and compared to samples from GF and conventional rodents and other 419 
mammalian species, including humans. The five biomarkers investigated, the so-called Midtvedt 420 
criteria (i.e. conversion of cholesterol to coprostanol, conversion of bilirubin to urobilinogens, 421 
20 
 
degradation of β-aspartylglycine, degradation of mucin, and the absence of fecal tryptic activity 422 
(23)) are claimed to reflect host-bacterial interactions, independent of the intestinal localization of 423 
the bacteria involved and the kind of species. With regard to these criteria, faecal samples from 424 
ASF mice showed patterns more resembling GF rather than conventional mice (23), which 425 
complemented previous results demonstrating an abnormal microbiota in SPF mice (90). Although 426 
this could be due to one of the limitations of ASF, i.e. its low diversity, ASF mice were shown to 427 
be immunologically, reproductively and metabolically similar to conventional mice (23). The 428 
Midtvedt criteria were also used to assess the suitability of SIHUMI(x) as a model microbiome. 429 
SIHUMI(x)-associated rats shared four criteria with conventional rats, of which three were, 430 
however, less pronounced (27).  431 
 A major difference between ASF and a consortium such as SIHUMI(x), is the fact that the 432 
latter involves human-derived bacterial strains. Most members of recently developed communities, 433 
except for Oligo-MM, are of human origin as well. This may be obvious, given the fact that, 434 
although their microbiota is similar at the division (superkingdom) level, 85% of the microbial 435 
genera and species detected in mice are not found in humans (91). Although qualitatively, humans 436 
and mice share a largely similar core, their intestinal microbiota is quantitatively very different 437 
(87). On the other hand, the development of small intestinal immune maturation was found to be 438 
host-specific, with humanized mice resembling more closely GF mice than mice associated with a 439 
murine microbiota (92). This host-specificity might also, at least partially, explain the unsuccessful 440 
colonization of piglets with ASF (52). Additionally, humanized rodent models were claimed to 441 
have been utilized mainly for short-term biomedical research studies (14). The question remains 442 
how human-derived bacteria would adapt during long-term colonization and vertical transmission 443 
in murine hosts (14, 93, 94), and thus, which kind of microbiota would be most reliable to study 444 
host-microbe interactions when using murine hosts. The maximum colonization time reported in 445 
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the studies discussed here (Table 1a-c) was less than one year. With respect to vertical transmission, 446 
stability after transfer to offspring has been addressed mainly for murine microbiota only (ASF 447 
(95) and Oligo-MM (22)). Within the humanized defined communities, SIHUMI(x) is an 448 
exception, of which bacterial concentrations in caecum were verified between founder rats as well 449 
as their offspring. At the age of eight weeks, SIHUMIx-rats harboured similar bacterial levels as 450 
their founders, but not at two weeks (except for E. coli) (27). 451 
Simplified versus complex communities 452 
The distinction between minimal communities, with two or three members, and larger defined 453 
communities is not black-and-white. For instance, ASF, initially used as a microbiota to standardize 454 
mouse models, slowly adopted the role of a minimal community, instead of one representing the 455 
normal microbiota of mice. Nonetheless, the simplicity of a defined community also has some 456 
advantages over more complex communities. The limited nature of ASF should, as proposed by 457 
Brand et al., allow investigators to evaluate the in vivo effect of the removal or addition of bacterial 458 
species on mucosal homeostasis and colonization dynamics, or potentially, factorial interactions of 459 
the community (14). Indeed, some of the studies discussed here (Table 1a-c) used only a subset of 460 
the ASF species or added species to already established defined communities, including ASF and 461 
SIHUMI(x). Additionally, one- and two-member communities could be applied to model aspects 462 
of a more complete microbiota, such as depletion of certain dietary compounds or metabolites (86). 463 
Finally, as already discussed, a simplified consortium makes each species traceable, as opposed to 464 
a very complex community (28, 40). 465 
 On the other hand, complex communities might more closely resemble the normal human 466 
gut microbiota and are more likely to confer colonization resistance to opportunistic pathogens, 467 
which has been a frequently mentioned criterion in the studies described above. In the 1980s, Freter 468 
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and co-workers formulated the nutrient-niche theory, which states that a certain bacterium can only 469 
successfully colonize if it is able to use a specific limiting nutrient more efficiently than its 470 
competitors (96). This implies that colonization resistance correlates with community complexity, 471 
as supported by several studies (22, 36, 97). Freter’s theory was corroborated in a recent study in 472 
which the relative abundance of each species of a ten-membered community was correctly 473 
predicted based on the concentration of individual dietary ingredients (41). The theory assumes, 474 
however, an environment in which bacterial growth is balanced and nutrients are perfectly mixed, 475 
whereas in reality bacteria are metabolically flexible (i.e. they have the ability to switch nutrient 476 
source) and nutrient levels in the gut are spatiotemporally heterogeneous (reviewed in (98, 99)). 477 
 Metabolic flexibility was hardly addressed in the studies discussed in this review. Some 478 
researchers did assure the inclusion of species in a defined community that, as a whole, was able 479 
to thrive on a wide range of nutrients. Once established in vivo, however, the behaviour of the 480 
community was seldomly addressed or only for a single species. This could be due to the fact that 481 
most of the included studies focused primarily on the effects of the whole microbiota or a subset 482 
of species on the host (host-microbe), rather than the exact nutrient niche occupation by its separate 483 
species (microbe-microbe interactions). Exceptional is a recent study, which quantified the in vivo 484 
response of both mucin-specialists (A. muciniphila and Barnesiella intestinihominis) and -485 
generalists (B. caccae and B. thetaiotaomicron) upon fibre deprivation (43). A fibre-deficient diet 486 
stimulated the expansion and activity of the mucus-degrading bacteria, promoting epithelial access 487 
and pathogen-induced colitis (43). 488 
 With respect to spatiotemporal heterogeneity, Oligo-MM12 was used to verify that the 489 
bacterial compositions in the large intestinal outer mucus layer and the intestinal lumen are 490 
significantly different (26). Due to extensive mucus shedding and mixing in the lumen, however, 491 
the differences may be relatively small (98). Indeed, it was recently shown that, at microscale level, 492 
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the proximal colon should be viewed as a partially mixed bioreactor rather than a clearly 493 
compartmentalized gut section with spatially segregated communities. A next step would be to 494 
quantify the distribution of nutrients and metabolites and the role of host factors such as diet, gut 495 
motility and mucus composition (48). Vice versa, it would be interesting to study the effect of 496 
spatial organization on relevant host parameters, which were unfortunately not addressed in the 497 
latter study. The authors did admit that the 15-membered community used may not be complex 498 
enough to demonstrate stronger spatial associations with food particles, host cells and mucus (48), 499 
reinforcing, all in all, the need for more complex communities.  500 
 Both metabolic flexibility and spatiotemporal heterogeneity allow for increased community 501 
diversity, which is thought to be crucial for ecosystem robustness (98). Defined communities 502 
enable the precise investigation of both concepts, but, on the other hand, the question remains 503 
whether they can be made sufficiently complex to properly address these issues. 504 
Bottom-up versus top-down approaches 505 
One way to obtain a more complex model community is to start with a complex sample, e.g. human 506 
stool, and narrowing the amount of species down via one or more enrichment steps, e.g. by 507 
culturing on selective media (top-down approach (100)) or using fermentation models. Table 1a-c 508 
includes only a few examples with regard to normal microbiota (Oligo-MM12 (22), (40)). The 509 
majority of the studies listed in Table 1a-c used a bottom-up approach, in which single, previously 510 
cultured and characterized strains are combined into a synthetic bacterial community, e.g. based 511 
on selection criteria previously mentioned, and administered to germ-free animals. An advantage 512 
of the latter method is the known composition of the microbiota, as previously emphasized. A 513 
drawback, however, is formed by the risk that the desired phenotype (in this case a normalized 514 
host) cannot be entirely recapitulated (100). 515 
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Future design 516 
A probably more important question is whether a normal microbiota actually exists. In the 1970s, 517 
Freter et al. concluded that significant fluctuations occur in the normal microbiota and that there is 518 
“no such a thing as a reproducible and precisely definable ‘normal enteric flora’”. Instead, they 519 
considered the F-strains collection most optimal to use as a microbiota representing a “state which 520 
is sometimes found in ‘normal’ individuals” (34). Clearly, the concept of the normal microbiota 521 
has changed over time and has evolved with the development of techniques to sequence the human 522 
gut microbiome, with increased insight into its composition, dynamics and function. Recently, 523 
researchers aimed to draw the compositional functional core of the human gut microbiota, or the 524 
core microbiome. They emphasized that the gut microbiome should be considered as a complex 525 
landscape, with both common and individual characteristics, and alternative stable states with 526 
respect to composition, structure and function (101). They listed a top set of 50 bacterial genus-527 
like taxa that are part of the phylogenetic core, a common core of bacterial taxa shared by the 528 
majority of (adult Western) human individuals, based on data from previous studies (101-103). 529 
This core may include keystone species, whose role are crucial for ecosystem structure and 530 
function, for instance the breakdown carbon sources to support the growth of other core members 531 
(104, 105). Mapping this core including its key stone species, and comparing it with diseased 532 
microbiota, could increase our understanding of a normal microbiota and facilitate the design of a 533 
defined community representative of a healthy human gut microbiota. Next to the phylogenetic 534 
core, increased insight into the minimal intestinal metagenome (106) and the active functional core 535 
(107) within the human gut ecosystem might provide new criteria for assessing the ‘normality’ of 536 
a designed defined community. The paradigm seems to shift from rather black-box-like measures, 537 
such as the Midtvedt-criteria, to actually understanding the function of the gut microbiota and the 538 
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contribution of its individual species. Subsequently, this approach could allow a more thorough 539 
comprehension and more accurate design of age-, region- and disease-specific defined 540 
communities.  541 
 Although this review primarily focusses on bacterial communities, it should be mentioned 542 
that the human (gut) microbiome also includes fungi, archaea, microeukaryotes and many viruses, 543 
mainly bacteriophages. A study from 1980 included a ‘yeast fungus’ in a defined hexaflora, but the 544 
specific role of this microbe was not addressed (108). One of the few studies in this area addressed 545 
the interaction between the murine host, an archaeon (Methanobrevibacter smithii) and a bacterium 546 
(B. thetaiotaomicron) (109). In addition, the same research group designed a gnotobiotic animal 547 
model with a simplified defined gut community to study phage-bacterial host dynamics (45). In 548 
parallel with the healthy gut microbiome, researchers recently mapped the healthy gut phageome 549 
(110), but this field is still in its infancy. It is reasonable to assume that, with increasing insight into 550 
the role of non-bacterial gut microbes in host-microbe interactions, the design of defined microbial 551 
communities becomes more representative of the whole human gut microbiome. 552 
Critical Evaluation of Defined Communities In Vivo: The Host 553 
Next to the discussion on the exact composition of the defined microbial community, the selection 554 
of the host animal to study host-microbe interactions is critical. Rodents are the most commonly 555 
used mammalian models in which defined communities have been applied. The suitability of 556 
rodents as model for the human host was extensively reviewed elsewhere (10) and goes beyond the 557 
scope of this review. In summary, murine intestines are anatomically, histologically and 558 
physiologically very similar to human intestines, but size, metabolic rates and dietary habits differ 559 
largely, leading to qualitative and quantitative differences in microbial composition (10). With 560 
respect to the gnotobiotic models discussed in this review, there are some additional discrepancies 561 
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to be mentioned. The high value of using gnotobiotic animals as models of humans, i.e. their known 562 
composition and controllability, seem to be weakened by poor control of host parameters known 563 
to influence the human gut microbiome, such as diet, genotype, sex, part of the gut studied, age 564 
and the immune system. 565 
Host parameters influencing the microbiota 566 
 Diet is a complex and strong determinant of gut microbiota composition (reviewed in (111, 567 
112)). The individual species levels were assessed of a ten-membered defined community in mice 568 
fed with diets systematically varying in protein, fat, polysaccharides and simple sugars, in order to 569 
develop a model to predict the variation in species abundance. Next, the model was validated with 570 
48 random combinations and concentrations of four ingredients selected from a set of eight human 571 
baby foods. Approximately 60% of the variation in species abundance could be explained by the 572 
known concentrations of pureed foods (41). This study exemplified the application of defined 573 
communities to systematically assess the response of individual gut members to various food 574 
components, which are, moreover, typical for the human diet. Clearly, a standardized diet of a 575 
laboratory animal is different from that of humans, which varies per region, season, individual taste 576 
and even per day. Some studies listed in Table 1a-c incorporated a previously developed prototypic 577 
“Western style” diet (27, 32, 39, 42, 46, 85), containing high amounts of saturated and unsaturated 578 
fats and carbohydrates commonly used as human food additives (i.e. sucrose, maltodextrin and/or 579 
corn starch). A lack of standardization in lab animal feeding protocols, however, has been 580 
emphasized previously for instance with respect to diet composition and texture (113) and indeed, 581 
diets used by studies discussed here are highly variable (Table 1a-c). Moreover, in ~40% of the 582 
studies, the diet was not clearly defined or not even reported, which is alarming given the large 583 
impact of diet on the gut microbiome.  584 
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 The choice for mouse genotype also varied per study (Table 1a-c), although an effect of 585 
host genotype on microbiota composition was established within species (114-118). These results 586 
were corroborated by studies with defined communities such as ASF (119) and SIHUMI(x) (64). 587 
Additionally, colonization of different mouse strains with SIHUMI(x) demonstrated host-specific 588 
caecal levels of polyamines and SCFAs (31). In mice associated with B. longum and B. 589 
thetaiotaomicron, host genetic background was found to affect the overall transcriptome of the 590 
latter bacterium, but not the expansion of the bacterial substrate range of this bacterium (84). 591 
Obviously, defined communities allow the careful investigation of such host-dependent effects, but 592 
validation of host-microbe interactions in a wide range of host strains seems crucial before drawing 593 
conclusions and extrapolation to humans.  594 
 Although reports on the effect of gender have been contradictive (106, 117, 120-124) it 595 
might be a crucial determinant in gut microbiota composition and/or behaviour. In turn, commensal 596 
microbiota was shown to affect sex hormone levels (125, 126). Sex differences in gut microbiota 597 
composition were, recently, comprehensively investigated in 89 common inbred mouse strains. 598 
After excluding confounding by host genetics, diet, age or cage effects, the researchers detected 599 
gender-specific differences in taxa abundances and diet responses. These differences could be 600 
partially explained by sex hormones (127). Among the studies discussed here (Table 1a-c), one 601 
reported differences in metabolic profiles in urine and plasma between both sexes, but no 602 
explanation was put forward (39). In an older study, male mice were found more susceptible to 603 
death after C. botulinum infection, which could be explained by their coprophagic behaviour or a 604 
more general higher susceptibility to disease (36). In contrast, other studies reported an absence of 605 
gender-specific effects on, for instance, levels of Oxalobacter formigenes colonized in ASF mice 606 
(20) or assembly of a synthetic microbiota (43). Whereas some studies discussed here (Table 1) 607 
reported to have used a gender-mixed population, others included only one gender (n = 12 of 53 608 
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studies), in which male more often than female (nine vs. three) animals were used. Remarkably, 609 
the establishment of SIHUMI(x) was verified in both genders, whereas the effect of dietary fibre 610 
was tested in male and the effect of high-fat diet was investigated in female rats (27). A similar 611 
discrepancy was found in a study that assessed the effect of five fermented milk product strains in 612 
human female twins, but male gnotobiotic animals. Although microbiota responses were more or 613 
less similar in both species (40), such a gender-mismatch may complicate translation. Lastly, not 614 
all studies clearly reported the gender used per experiment, and approximately half of the studies 615 
did not report animal gender at all. This too, may hinder data reproduction and, more importantly, 616 
translation. 617 
 Defined communities allow the quantitative comparison of microbial compositions along 618 
the GIT, within and between models. ASF-associated mice were used to quantitatively demonstrate 619 
that the microbiota of the colon is poorly reflected in faecal samples (95). Relative abundance of 620 
species were also different between faeces (rectal swabs) and colon in pigs colonized with a defined 621 
microbiota (63). In rats colonized with SIHUMI(x), however, bacterial concentrations of caecum, 622 
colon and faeces were similar (27). Additionally, increases in relative abundances of mucin-623 
degrading bacteria in caecum and colon upon switching to a fibre-free diet, were reflected in faeces 624 
(43). In a mouse model associated with a 12-membered community, individual bacterial levels 625 
were also similar between faeces and caecum (46). These conflicting results could be explained by 626 
various factors, including host, community composition and sampling time. Irrespective of the 627 
actual difference between GIT sites, it is disappointing that some other studies relied solely on 628 
faecal bacterial content. In a study applying a 92-membered community, for instance, not even half 629 
of the members could be detected in faeces. Other species may have established themselves in 630 
different regions of the gut, but this was beyond the scope of the paper (51). Nevertheless, due the 631 
invasiveness of sampling, systematic studies comparing colonic and faecal bacterial content are 632 
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lacking in humans as well (99, 112). The variation in GIT sites looked at by the studies included 633 
in Table1a-c, makes it hard to compare the colonization pattern of the defined communities to 634 
natural colonization. Apart from differences along the GIT, capturing the transversal heterogeneity 635 
within one compartment may be crucial for properly modelling and understanding host-microbe 636 
interactions, as discussed above. 637 
 The age at which animals are colonized was quite variable among the studies, including 638 
animals bred with the desired defined community as opposed to GF animals colonized with the 639 
community of interest to create a gnotobiotic animal model. In the latter case, animals are 640 
inoculated at various time points among studies, whereas timing of microbial colonization was 641 
demonstrated to impact, amongst others, immune maturation (128, 129), mucosal homeostasis 642 
(130) and gut-brain axis communication in mice (131). Moreover, as previously discussed, 643 
colonization time of animals in studies discussed here (Table 1a-c) was limited. Nevertheless, some 644 
studies confirmed the stability of their defined community of interest over time and even over 645 
generations, which should be sufficient to draw conclusions within a specific colonization time 646 
window. This does, however, not allow to infer any information on the long-term effects of 647 
colonization. 648 
 A last factor determining gut microbiota composition and behavior is the immune system, 649 
which in turn is influenced by, amongst others, aforementioned factors and the gut microbiota 650 
itself. Looking at the studies discussed here (Table 1a-c), several researchers investigated 651 
immunological parameters such as serum immunoglobulin levels and the presence of (subsets of) 652 
immunological cells in the gut. Nevertheless, due to the complexity of the immune system, it is 653 
hard to quantify and compare the model hosts used with respect to immunological parameters. The 654 
key findings on the interactions of gut microbiota members and their products with the immune 655 
system have been recently reviewed elsewhere (100). The authors emphasized the value of minimal 656 
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microbiomes and subsequent standardized (animal) models. Determining the effects of specific gut 657 
microbiota on the host, could help to identify host-microbe interactions that shape the immune 658 
system (100). Most studies discussed in this review did not make a distinction between the 659 
contributions of each specific microbe to immunological effects observed. 660 
The advantages and the levels of controllability of gnotobiotic research, as well as its 661 
pitfalls in practice, as outlined above, are summarized in Table 2.  662 
Validation of in vivo models 663 
As emphasized earlier, differences exist between humans and animals, not only limited to their 664 
intestinal microbiota. In line with the question what a normal or healthy intestinal microbiota 665 
defines, one could ask: “When is the animal model sufficiently representative of the human 666 
situation?” With regard to the studies discussed here (Table 1a-c), diverse host criteria are applied. 667 
For the models exploiting a murine microbiota, validation is relatively easy. Most researchers 668 
aimed to normalize GF hosts to conventionally raised animals, thereby focusing on host parameters 669 
such as caecal size or weight (9, 22, 33, 34). With respect humanized mice, validation is more 670 
complicated, but some studies made an effort. For instance, total bacterial numbers in feces and 671 
fecal SCFA levels between humans and SIHUMI(x) rats were evaluated, and a previously reported 672 
increase of Erysipelotrichaceae upon high-fat diet in humans was mirrored in SIHUMI(x) animals 673 
(27). Other host parameters (e.g. immune system or other systemic parameters) were, however, not 674 
taken into account. Similarly, validation was lacking in other studies applying SIHUMI(x), in 675 
which, moreover, mice were used instead of rats (28, 30-32).  676 
 A better example was recently described in a study in which the effect was tested of a 677 
fermented milk product in both humans and gnotobiotic mice humanized with a 15-membered 678 
microbiota. The proportional representation of the intestinal bacterial species and genes and 679 
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metabolic changes upon introduction of the probiotic strains, were hardly different between mice 680 
and men, but the researchers also acknowledged the limitations of their gnotobiotic animal model 681 
with respect to translatability (40). In most other studies (Table 1), control groups were limited to 682 
conventionally raised and GF animals or animals with a control treatment, for which translatability 683 
of the results to the human situation remains speculation.  684 
Defined Communities In Vitro 685 
As opposed to in vivo models, the use of defined communities to study host-microbe interactions 686 
in vitro has been limited, so far, although the development of sophisticated in vitro model systems 687 
is advancing rapidly. In this section we discuss in vitro models in which defined communities have 688 
been applied or could be applied to study host-microbe interactions. A distinction is made between 689 
models focused on the microbiota (e.g. composition and characteristics), and those that were 690 
designed to realistically represent the human host in vitro. Figure 1 summarizes all existing in vitro 691 
models of the human host and microbiota, illustrating how their interactions can be studied 692 
combining advanced in vitro cell based systems with defined communities. Ultimately, the goal is 693 
to combine best of both worlds.  694 
Modelling the intestinal microbiota in vitro 695 
The use of fermentation models has proven successful in modelling the intestinal microbiota in 696 
vitro, ranging from short-term batch incubations to multi-compartmental continuous systems. As 697 
discussed already, most defined communities applied in vivo (Table 1a-c) were constructed bottom-698 
up, by selecting species based on their function, prevalence or other criteria. Alternatively, 699 
communities can be composed top-down by inoculating GIT-mimicking chemostats with human 700 
faeces. Well-known examples of these chemostats, such as the MacFarlane/Gibson three-stage 701 
continuous culture system, (M-)SHIME, EnteroMix, Lacroix Model and TIM-2, have been 702 
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extensively reviewed elsewhere (132-134). The high reproducibility, stability, and complexity of 703 
bacterial communities cultured in chemostats (135, 136) has allowed the development and 704 
application of representative communities of the human intestinal microbiota in vitro. Most of these 705 
models, however, did not include a host component. The HMITM module comprised a promising 706 
exception in which first, faeces from a healthy volunteer was fed into an adapted SHIME system, 707 
with fluid compartments mimicking the stomach, small intestine and ascending colon. 708 
Subsequently, the SHIME-effluent was exposed to an artificial mucus layer, separated by a semi-709 
permeable membrane from a compartment containing Caco-2 cells. This module allowed the co-710 
culture of bacteria with enterocytes up to 48 hours (137), which is discussed in more detail below.  711 
Modelling the host in vitro 712 
With respect to well-established defined communities, the probiotic cocktail VSL#3 and the faecal 713 
transplant substitute MET-1 have been tested on various human or animal intestinal cell lines 714 
(Caco-2, T84 and HT-29) (e.g. (138-140)). In most studies, however, the use of bacterial lysates or 715 
conditioned media was preferred over live bacteria (e.g. (72, 141-144)), because the – mainly 716 
anaerobic – gut bacteria cannot survive under the aerobic conditions needed for intestinal cell 717 
culture. In these 2D models, the interaction with the immune system or other tissues, cannot be 718 
studied. Although the direct effect of VSL#3 was tested on spleen and dendritic cells (145, 146), 719 
tissue-tissue interactions were lacking in these models. This problem can be (partially) solved in 720 
Transwell co-culture models, in which bacteria, mucosal immune cells and intestinal epithelial 721 
cells can be studied together (147). A Transwell model with an apical anaerobic compartment 722 
enabled the co-culture of an anaerobe bacterium with an intestinal cell line to study host-microbe 723 
interactions (148). Still, these cell lines lacked their tissue-specific context, including all major 724 
types of epithelial cells (e.g. Goblet cells, enterocytes, enter endocrine and Paneth cells) organized 725 
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in crypts and villi. Moreover, as cell lines are tumor-derived, their epithelial characteristics are 726 
affected. These issues have been overcome by the development of gut organoids, self-organizing 727 
3D epithelial structures derived from intestinal stem cells (149) or human pluripotent stem cells 728 
(150). The use of organoids to study host-microbe interactions was reviewed elsewhere (151). The 729 
closed structure of organoids, in which the lumen is sealed with epithelial cells and a mucus layer, 730 
may facilitate the establishment of hypoxia in the core lumen (151). The anaerobic pathogen C. 731 
difficile survived up to 12 hours within organoids, but luminal oxygen levels still ranged from 5-732 
15%, which may be tolerated by specific strains of C. difficile only (152). More recently, 733 
researchers developed an organ culture system for the mouse intestine, in which the stromal and 734 
hematopoietic components of the normal intestine were preserved ex vivo. The device supported 735 
the survival and growth of both anaerobic and aerobic microbiota, allowing the investigation of 736 
their effects on neuronal parameters (153). 737 
The co-culture of defined microbial communities with human cells in Transwells, organoids or 738 
organ culture systems has been limited, probably owing to the static nature of these models. More 739 
advanced in vitro models to study host-microbe interactions have been developed (as recently 740 
reviewed in (133)) of which only a few have hitherto allowed the co-culture of multiple bacteria 741 
with intestinal cells or cell lines. 742 
 Organ-on-a-chip technology is an emerging concept within biomedical research, to replace 743 
conventional cell culture and animal testing. Organ-on-chips are microfluidic devices in which 744 
cells are cultured with organ-relevant spatiotemporal chemical gradients and dynamical 745 
mechanical cues, thereby aiming to reconstitute the structural tissue arrangements and functional 746 
complexity of living organs in vitro (154). Several gut-on-chips have already been developed (155-747 
158), only one in which multiple intestinal bacteria were successfully cultured (158). In this device, 748 
two channels simulating the gut lumen and a blood vessel are separated by a membrane coated with 749 
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extracellular matrix and Caco-2 cells (158). As opposed to cell monolayers and organoids, the gut-750 
on-a-chip is a dynamic model: shear stress and gut peristalsis are mimicked by continuous medium 751 
flow and stretching/relaxing of the membrane, respectively. Interestingly, these environmental cues 752 
stimulated Caco-2 cells to undergo differentiation into four types of intestinal epithelial cells, 753 
organized in 3D villi-like structures (159) Also, the successful incorporation of endothelial cells 754 
and peripheral blood mononuclear cells, was demonstrated (160). The authors claimed the 755 
successful cultivation of a single bacterium ‘on chip’ (Lactobacillus rhamnosus) for more than one 756 
week (158) and the eight-membered VSL#3 for at least 96 hours (160). The viability of the 757 
probiotic bacteria was, however, solely based on imaging, and which species exactly succeeded in 758 
‘colonizing’ the crypts, was not exactly determined. The growth of anaerobic bacteria in this device 759 
has not yet been reported.  760 
 In contrast, another recent study reported the successful co-culture of strictly anaerobic 761 
bacteria, B. caccae, with L. rhamnosus and Caco-2 cells. In their microfluidic-based model 762 
mimicking the human gut, HuMiX, bacteria were grown in a separate, anoxic compartment (161). 763 
Similarly, the HMITM module allowed the investigation of bacteria for up to 48 hours under 764 
microaerophilic conditions. FISH analysis revealed the presence of strict anaerobic bifidobacteria 765 
in the upper part of the mucus layer and the positioning of F. prausnitzii at the oxic-anoxic 766 
interphase (137). In both the HuMiX and HMITM module, however, a mucin-coated attachment 767 
membrane prevented direct or natural contact between host and microbe. Moreover, as opposed to 768 
the gut-on-a-chip, gut peristalsis was not mimicked and the formation of the main epithelial cell 769 
types or crypts, were not reported in these models (137, 161).  770 
 A promising development in gut-on-chip technology is the incorporation of 2D organoids, 771 
which grow in a plane rather than in clumps, in the chip device (162), combining the advantages 772 
of organoids (tissue differentiation) with those of gut-on-a-chip technology (controllable flow, 773 
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mechanical cues and tissue-tissue interaction). To date, the cultivation of a defined intestinal 774 
microbiota in this device, has not yet been reported.  775 
Validation of in vitro models 776 
In comparison with animal models, validation of in vitro models is even more challenging. The 777 
cellular processes studied in Transwells, organoids or gut-on-a-chips, cannot be readily validated 778 
in human subjects. On the other hand, however, such sophisticated in vitro models enable the 779 
investigation of processes that cannot be readily studied in humans, increasing our understanding 780 
of the molecular mechanisms of certain bacterial compounds or products. Furthermore, they allow 781 
the elimination of potentially confounding factors present in in vivo models, such as the immune 782 
system. At the same time, this is also one of the major drawbacks of aforementioned in vitro 783 
models: as opposed to in vivo models, they lack a systemic component, whereas the impact of the 784 
gut microbiota on human health extends beyond the GIT. The emergence of organ-on-chip 785 
technologies has led to the concept of a ‘human-on-a-chip’ (163), but its implementation in 786 
research is still at an early stage. Nevertheless, the road to such a human-on-a-chip may be just as 787 
interesting. ‘Rebuilding’ the human body through assembly of its separate parts (lung-on-a-chip, 788 
gut-on-a-chip, kidney-on-a-chip, etc.), might increase our understanding of these building blocks 789 
and their contribution to the whole.  790 
Conclusions and Future Outlook 791 
Our understanding of the human gut microbiome has rapidly grown over the past decades, which 792 
has definitely supported the design of defined communities representative of the human gut 793 
microbiome. Whereas defined communities were initially aimed to normalize germ-free hosts to 794 
conventionalized mice, they could be a valuable tool to study host-microbe interactions, because 795 
of their controllability and traceability. For the same reasons, defined communities have a high 796 
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potential for therapeutic application. In this review, however, we showed that these rationally 797 
designed consortia have been applied in in vivo models that are not entirely representative of the 798 
human host environment. Next to the obvious and frequently discussed differences between mice 799 
and men, we also discussed the power of gnotobiotic animals has been further undermined by poor 800 
control of the host parameters known to affect gut microbiota composition and behaviour.  801 
 Simultaneously with the increasing knowledge on the human gut microbiota, the 802 
implementation of more advanced in vitro models of the human gut is accelerating, with the 803 
development of stem-cell derived organoids and gut-on-a-chip approaches. Although the research 804 
is still in its infancy, these systems might partially replace the use of animal models. This 805 
development is beneficial not only for ethical and – on the long-term – financial reasons, but also 806 
from a scientific perspective. Human-inspired in vitro systems allow us to model and capture host-807 
microbe interactions at a more fundamental and controlled level.  808 
 Both the design of defined communities and in vitro models of the gut have not yet reached 809 
their plateau. The former can be improved, via either bottom-up or top-down approaches. Key is 810 
to further expand our knowledge about the intestinal microbiome in health and disease, in which 811 
the NIH Human Microbiome Project and the European MetaHit project have played a crucial role 812 
(106, 164) (bottom-up). The characterization of gut microbiota and genome sequences facilitates 813 
the in silico prediction of host-microbe interactions through constraint-based genome-scale 814 
metabolic modelling (165) or other types of mathematical modelling (166) and, subsequently, the 815 
in silico design of representative defined communities (bottom-up). Further exploring our whole 816 
microbiome, including phages, fungi and archaea, will revolutionize the design of microbial 817 
communities as well (bottom-up). Lastly, the increased ability to reproducibly culture the 818 
microorganisms in human faeces in vitro using well-established fermentation technologies (135, 819 
167) may open the avenue to study human faeces-derived, functionally-enriched defined 820 
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communities at a more personalized level (top-down). In this way, both health- and disease-related 821 
microbiota can be easily reproduced. The same level of personalization can be obtained on the host 822 
side. For instance, the implementation of 2D organoids from patient-derived induced pluripotent 823 
stem cells in in vitro systems, such as the gut-on-a-chip with, can lead to highly personalized 824 
screening devices. 825 
 All in all, these models will provide a basis for the rational development and screening of 826 
novel therapies targeting intestinal diseases, ranging from anti-, pre- and probiotics to manipulate 827 
existing gut microbiota, to therapeutic microbes (168), faecal microbiota transplantation (169) and 828 
stool substitutes (77). 829 
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FIGURE LEGENDS 1424 
Figure 1. In vitro models of the human gut and gut microbiota. Models are organized from bottom to top, 1425 
with the most representative and complex at the top and the most controllable and traceable - with respect 1426 
to host parameters or microbial species - at the bottom.   1427 
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Table 1a. Studies using defined communities to study host-microbe interactions in vivo: Specifically named communities (n = 30) 
The following study characteristics are listed: microbial consortium name (if applicable), taxonomic affiliation, strain source, host species and strain, part of the gut studied, no. of animals per 
experimental group, diet, sex, age and study outcomes reported.  
* Two different strains tested are counted as one species. Strains were not always reported. Pathogenic species, in case of an infection model, are not included. 
**The colonization time includes the time from colonization (0 in case of transfer of microbiota to offspring) till and including the time of sacrifice or end of experimental (e.g. dietary) 
manipulations, in case this is clearly stated in the paper. If age is given and animals are colonized at birth, the age is included in colonization time. 
*** Study outcomes are only reported for the animals colonized with the defined community of interest 
Abbreviations: LP = lamina propria; MLN = mesenteric lymph nodes; MPO = myeloperoxidase; NR = not reported; SCFA = short-chain fatty acids; Treg = regulatory T-cell 
Ref. Name consortium (no. of species*) Phylum division Strain 
source 
Host 
species 
(strain) 
Part of the gut studied No. of 
animals 
per 
group 
Chow Sex 
(M/F, 
both 
or 
NR) 
Age (col. 
time**) 
Study outcomes*** 
 
(9) Schaedler flora (5)  
2 Lactobacillus sp., anaerobic 
streptococcus sp. (group N), Bacteroides 
strain, Enteroccocus sp., coliform strain 
 Mouse Mouse (NR)  20 NR NR 4 wk  
(3 wk - 4 
mo) 
Colonization pattern; 
caecal size 
Altered Schaedler Flora (ASF) 
(36)  ASF (8) 
ASF356: Clostridium species  
ASF360: Lactobacillus intestinalis or 
acidophilus  
ASF361: Lactobacillus murinus or 
salivarius 
ASF457: Mucispirillum schaedleri  
ASF492: Eubacterium plexicaudatum  
ASF500: Pseudoflavonifractor sp. 
ASF502: Clostridium sp. 
ASF519: Parabacteroides distasonis 
 
Mouse Mouse 
(HA/ICR) 
 
30 NR Both Adult  
(14-56 d) 
Death after C. botulinum 
infection; faecal C. 
botulinum toxin excretion; 
colonization pattern of C. 
botulinum  
(170) Mouse Rat  
(F344) 
 
1-5  Sterile 
food 
(Charles 
River) ad 
libitum 
M NR  
(2 wk) 
Hepatic genotoxicity of 
mononitrotoluene isomers; 
metabolic activation of 2NT 
by intestinal bacteria; 
caecal bacterial content  
(16) Mouse Mouse 
(scid C.B-
17) 
 
4-6 Autoclaved 
pelleted 
diet ad 
libitum 
NR NR  
(8-12 wk 
post 
reconstit
ution 
(After H. hepaticus 
infection) Rectal prolapse; 
clinically severe disease; 
grossly thickened colon, 
cecum and rectum on 
necropsy; colonic 
65 
 
CD4+ T-
cells) 
inflammation score; colonic 
epithelial cell proliferation; 
histopathology 
(15) Mouse Rat  
(HLA-B27 
on 33-
3/F344)  
7-11  NR at 
least 
M 
2 mo  
(1 mo) 
Gross gut score, levels of 
MPO and IL-1B in caecal 
tissue; histologic 
inflammatory score of 
caecum and antrum 
(171) Mouse Mouse 
(C3H/HeN) 
 
4-8 Irradiated 
diet 
(Harlan 
Teklad) 
NR 6-8 wk 
(9-14 wk) 
After colonization with H. 
bilis or B. hyodysenteriae: 
Caecal pathological gross 
and histological scores; 
serum IgG1 + IgG2a ab 
response 
(172) Mouse Mouse 
(C3H/HeN) 
 
7-10  Irradiated 
diet 
(Harlan-
Teklad) 
NR 6-8 wk  
(10 wk) 
Faecal bacterial contents; 
(after H. bilis infection:) 
caecal pathological scores; 
caecal histological changes; 
serum immunoglobulin 
(173) Mouse Mouse 
(SW) 
 
2-5  NR NR 6-9 wk 
(NR) 
Presence of Th17 cells and 
Foxp3+ regulatory cells in 
LP of small intestine 
(174) Mouse Mouse 
(C57BL/6) 
 
NR NR NR NR Total intestinal IgA and 
intestinal IgA anti-CBir1; 
proliferation of splenic 
CBir1 TgT-cells after CBir1 
gavage 
(175) Mouse Mouse 
(B6.Rag-/-) 
 
NR NR F 8-10 wk 
(10 d) 
Homeostatic and 
spontaneous proliferation 
of TCR Tg T-cells in LP 
(97) Mouse Mouse 
(C57BL/6) 
 5-8 Autoclaved 
chow 
NR 8 wk (at 
least 3 
dpi) 
After infection: S. 
Typhimurium levels in 
mesenteric lymph nodes, 
spleen, caecum and feces; 
caecal pathology score; 
66 
 
caecal microbiota density; 
bacterial content and 
microbiota complexity in 
feces 
(21) ASF (8,9) 
8: ASF 
9: ASF + Escherichia coli HA108 or 
HA107 
ASF (9) 
 
Mouse Mouse 
(C57BL/6) 
 
3 NR NR NR  
(119 d) 
No. of IgA plasma cells per 
intestinal villus in 
duodenum, jejunum, ileum 
and colon; IgA-bacterial 
binding in intestine; anti-
E.coli IgA titre 
(176) ASF (8) 
 
 Mouse Mouse 
(NMRI, 
C57BL/6, 
BALB/c, 
NIH Swiss, 
SW, NMRI, 
MyD88-/- 
Ticam1-/-, 
SMARTA, 
C57BL/6.CD
45.1+) 
 
3-10  NR NR NR  
(up to 28 
d) 
Caecal bacterial contents; 
colonic Treg cell response 
and relative IL-10 
expression in spleen, MLN, 
Peyer's patches, colonic 
and small intestinal LP, 
thoracic duct lymph; IL-17 
production; relative 
abundance of strains; 
microscopic localization in 
colon and small intestine 
(17) Mouse Mouse 
(Nod1 -/- 
and Nod2-
/- on 
C57BL/6) 
 NR NR NR 6-9 wk 
(NR) 
Caecal bacterial contents; 
intestinal tissue 
conductance and Cr-EDTA-
flux; E-cadherin protein 
expression and RegIII-
gamma mRNA expression 
in colon; survival, colitis 
disease severity, histology 
score and myeloperoxidase 
activity after DSS-induction; 
colonic IL-6, IL-10, MCP-1, 
IFN-c, TNF-a, IL-12p70 
levels  
(177) Mouse Mouse 
(C57BL/6) 
 NR Autoclaved 
food 
Both 8-12 wk  
(8-12 wk) 
REGIII-gamma RNA and 
protein expression in ileum 
and colon 
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(178) Mouse Mouse 
(C57BL/6 
and 
C57BL/6 
TSLPR-/-) 
 3-5 NR NR NR (28 d) Expression of thymic 
stromal lymphopoietin 
mRNA in intestinal 
epithelial cell or colonic LP 
(LP); percentage of CD4+ T 
cells secreting IL-17A and 
IFN gamma in the colonic 
LP and MLN; expansion of 
colonic Treg cells in colonic 
LP and MLN; expression of 
receptor for TSLP by CD4+ 
and regulatory T-cells 
(179) Mouse Mouse 
(NIH Swiss) 
 4 NR NR 3 d (3 d) Structure of myenteric 
plexus, nerve density, 
average no. of HuC/D-
positive myenteric neurons 
per ganglion, cell body size 
and average no. of nNOS-
positive neurons per 
myenteric ganglion in 
duodenum, jejunum and 
ileum; small intestinal 
motility (frequency and 
amplitude of muscle 
contractions) in duodenum, 
jejunum and ileum before 
and after general neural or 
specific nitrergic blockade 
(81) Mouse Mouse 
(C57BL/6) 
 5-14 per 
group 
Autoclaved 
mouse 
breeder's 
diet 
(Harlan), 
unlimited 
access 
Both 6-12 wk 
(3 wk) 
Colonic histology, 
inflammatory (MPO) 
activity, enteropathy 
(presence of faecal 
albumin) and cytokine 
expression; faecal 
microbiota profiles; colonic 
gene expression; 
proportion of T-cell 
subtypes in colonic LP and 
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other mucosal and 
systemic immune 
compartments 
(26) ASF (8) 
Oligo-MM12 was also used, but no host 
parameters were assessed 
 Mouse Mouse 
(C57BL/6) 
 3 (ASF), 
5-23 
(Oligo-
MM) 
NR Both NR Thickness of colon total 
and colon inner mucus 
(ASF); mucus turnover time 
(ASF); 
alpha diversity in colon and 
cecum (Oligo-MM) 
(20) ASF (8,9) 
8: ASF 
9: ASF + Oxalobacter formigenes 
ASF (9) 
 
Mouse Mouse 
(SW) 
 4-7 per 
group 
LM-485 
autoclavabl
e rodent 
diet, free 
access 
M 
(no 
gend
er-
effect 
obser
ved) 
3-9 mo 
(3-9 mo + 
6 wk) 
Bacterial levels in stomach, 
caecum, proximal colon 
and caecal mucosa; body 
weight; dietary oxalate 
intake; caecal and faecal 
oxalate levels; urine 
volume; urinary metabolite 
levels; caecal wet weight; 
caecal water metabolites 
Partial ASF 
(18) Partial ASF (6)  
ASF 356, 361, 492, 502, 519 and 500 
 
ASF 360 and 457 not colonized 
 
Mouse Mouse 
(NOD.MyD
88KO) 
None 9-23 NR Both NR (up to 
30 wk) 
Incidence of diabetes; 
histological scores of 
pancreatic islet destruction  
(19) Partial ASF (4,5) 
4: ASF360, ASF361, ASF457, ASF519 
5: 4 + Butyrivibrio fibrisolvens (type I, 
ATCC 19171 and type II, ATCC 51255) 
 
(4) 
(5) 
 
Mouse 
and 
bovine  
Mouse 
(BALB/c) 
 4-5  Autoclaved 
low-fiber 
diet (5SRZ, 
1813680) 
or high-
fiber diet 
(5SVL, 
1813901) 
or 
tributyrin 
diet (5AVC 
1814961) 
NR NR (2.5-5 
mo after 
colorecta
l cancer 
induction
)  
Colorectal tumor 
multiplicity, tumor size and 
tumor grade; levels of 
LDHA, lactate, butyrate, 
H3ac and total H3 in 
colonic tissue and tumors; 
luminal SCFA levels; H3ac 
and expression levels of 
Fas, p21 and p27 genes in 
colonic tissue and tumors; 
apoptosis and cell 
proliferation levels in 
colonic tissue and tumors 
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(22) 
 
Partial ASF (4,5,7,7) 
4: ASF356, ASF360, ASF361, ASF519 
5: ASF360, ASF361, ASF457, SB2 
[ASF502], ASF519 
7: ASF356, ASF360, ASF361, ASF457, 
ASF500, SB2 [ASF502] and ASF519 
7: 4 + E. coli Mt1B1, Streptococcus 
danieliae ERD01G, Staphylococcus 
xylosus 33-ERD13C  
 
(more under ‘Oligo-MM’) 
(4), (5) 
  
(7), (7) 
 
Mouse Mouse 
(C57BL/6) 
 4-6  NR Both 0 or 8-12 
wk (8-12 
wk or 40 
d) 
Faecal bacterial content; 
bacterial load of S. 
typhimurium in feces, 
caecum and MLN; relative 
caecal weight; functional 
genomic analysis of 
bacteria 
Oligo-MM 
(22) Oligo-MM (12, 15, 17)  
12, Oligo-MM: ‘Acutalibacter muris’ 
KB18, Flavonifractor plautii YL31, 
Clostridium clostridioforme YL32, 
Blautia coccoides YL58, Clostridium 
innocuum I46, Lactobacillus reuteri I49, 
Enterococcus faecalis KB1, ‘Bacteroides 
caecimuris’ I48, ‘Muribaculum 
intestinale’ YL27, Bifidobacterium 
longum subsp. animalis YL2, 
‘Turicimonas muris’ YL45 
Akkermansia muciniphila YL44 
15: 12 + 3 facultative anaerobes (E. coli 
Mt1B1, Streptococcus danieliae 
ERD01G, Staphylococcus xylosus 33-
ERD13C ) 
17: 12 + 5 ASF (ASF360, ASF361, 
ASF457, SB2 [ASF502], ASF519) 
Oligo-MM 
with 3 FA 
with 5 ASF 
Mouse Mouse 
(C57BL/6) 
 4-6  NR Both 0  
(8-12 wk) 
Faecal bacterial content; 
bacterial load of S. 
typhimurium in feces, 
caecum and MLN; relative 
caecal weight; functional 
genomic analysis of 
bacteria 
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 1429 
(25) Oligo-MM (12,13) 
12: Oligo-MM 
13: 12 + Clostridium scindens 
ATCC35704 
Oligo-MM 
+ C. scindens 
 
Mouse Mouse 
(C57BL/6) 
 5-8 NR NR 0  
(6-12 wk) 
Faecal and caecal bacterial 
contents; caecal levels of 
lipocalin-2; calprotectin 
expression in caecal tissue; 
histopathology of caecum; 
caecal bile acid 
metabolome 
71 
 
SIHUMI (x) 
(27) SIHUMI(x) (7,8) 
Anaerostipes caccae DSM(Z) 14662 or 
14667 
Bacteroides thetaiotaomicron DSM(Z) 
2079 
B. longum NCC 2705 
Blautia producta DSM(Z) 2950 
Clostridium ramosum DSM(Z) 1402 
E. coli K-12 MG1655 
Lactobacillus plantarum DSM(Z) 20174 
(x) Clostridium butyricum DSM(Z) 
10702 
SIHUMI 
SIHUMI(x) 
Human Rat (Spraque-
Dawley) 
 
 
3-21 Sterilized 
standard 
chow (g/kg: 
225 protein, 
50 crude fat, 
65 ash, 135 
moisture, 
480 N-free 
extract), 
fermentable-
fiber-free 
diet, inulin 
diet, pectin 
diet, high-fat 
and low-fat 
diet 
Both 0-3 
mo  
(2-38 
wk) 
Stability of microbiota in 
offspring; SCFA 
concentrations and pH in 
caecum, colon and feces; 
bacterial counts in 
caecum, colon and feces; 
Midtvedt criteria  
(28) SIHUMI(x) (8,9) 
8: SIHUMI(x) 
9: 8 + A. muciniphila ATCC BAA-835  
(9) Human Mouse (C3H)  5-10 NR NR 12 wk  
(5-15 
d) 
Bacterial cell numbers 
and proportions in 
caecum and colon; 
caecal and colonic 
histopathology score; 
expression of pro-
inflammatory cytokines 
in caecal and colonic 
mucosa; serum protein 
levels of pro-
inflammatory cytokines; 
cell number of S. 
Typhimurium in MLN and 
spleen; size of MLN; 
macrophage infiltration 
in caecal tissue; 
localization of A. 
muciniphila and S. 
Typhimurium; mucin 
formation, mucus 
72 
 
thickness, mucus 
composition and number 
of mucin-filled cells 
(30) SIHUMI(x) (8,9)  
8: SIHUMI(x) 
9: 8 + Fusobacterium varium ATCC 
8501 
 (9) Human Mouse 
(C3H/HeOuJ) 
 12  Irradiated 
standard 
chow R03-40 
F 0  
(8 wk) 
Body weight; dry mass of 
caecum and colon; 
bacterial content caecum 
and colon; polyamine 
concentrations in 
caecum and colon; SCFA 
concentrations in 
caecum and colon; 
histology of caecum and 
distal colon (thickness of 
crypt depth, epithelial 
layer, mucosa, 
submucosa, muscularis 
externa); mitosis and 
apoptosis of caecal and 
distal colonic tissue 
(31) Human Mouse (Prm/Alf, 
C3H/He) 
 12-
13  
Sterilized 
pelleted 
standard 
chow R03-40 
F 0  
(56 ± 1 
d) 
Length of small, large 
and whole intestine; 
thickness of muscle, 
crypt and villi in proximal 
and small intestine and 
colon; faecal and caecal 
microbial content; caecal 
concentrations of SCFAs 
and polyamines 
(32) SIHUMI(x) (7,8) 
7: SIHUMI(x) without C. ramosum 
8: SIHUMI(x) 
SIHUMI Human Mouse 
(C3H/HeOuJ) 
 3-9  Irradiated 
low-fat or 
high-fat diet 
ad libitum 
M 0 
(16 
wk) 
Body weight; body fat 
percentage; adipose 
tissue weight 
(epididymal, mesenteric 
and subcutaneous); 
energy intake; food 
efficiency; digestibility of 
high-fat diet; digestible 
energy; caecal and 
colonic bacterial content 
73 
 
SIHUMI(x) per species; blood 
glucose; leptin gene 
expression in epididymal 
tissue; liver weight; liver 
triglyceride levels; liver 
glycogen contents; 
expression of genes 
involved in lipid 
transport, lipid synthesis, 
cholesterol synthesis and 
lipid catabolism; gene 
expression of proteins 
involved in small 
intestinal glucose uptake; 
SCFA formation in 
caecum, colon and portal 
vein plasma; gene 
expression of SCFA-
related proteins in 
colonic mucosa; gene 
expression of lipid 
transport and storage 
proteins in ileum; 
parameters of intestinal 
permeability and low-
grade inflammation 
(29) SIHUMI(x) (8,9) 
8: SIHUMI(x) 
9: 8 + A. muciniphila ATCC BAA-835 
(9) Human Mouse 
(C57BL/6.129P2-
Il10tm1Cgn) 
 
5-6 Irradiated 
standard 
chow 
(Altromin 
fortified type 
1310; 
Altromin, 
Lage, 
Germany) ad 
libitum 
M 0 or 8 
wk (3 
wk) 
Body weight; 
histopathology score in 
submucosa, LP, surface 
epithelium, lumen; colon 
length; relative mRNA 
levels of Tnfa, Ifng, 
Reg3g; fecal lipocalin-2 
concentration; fecal and 
caecal bacterial levels; 
caecal histology; number 
of goblet cells per 100 
epithelial cells in caecum 
74 
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 1431 
 1432 
 1433 
 1434 
 1435 
 1436 
 1437 
 1438 
 1439 
 1440 
 1441 
 1442 
 1443 
 1444 
and colon; mucus layer 
thickness in colon; 
relative Muc2 mRNA 
levels in distal small 
intestine, caecum and 
colon 
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Table 1b. Studies using defined communities to study host-microbe interactions in vivo: Non-specifically named communities in rodents (n = 16) 
The following study characteristics are listed: microbial consortium name (if applicable), taxonomic affiliation, strain source, host species and strain, part of the gut studied, no. of animals per 
experimental group, diet, sex, age and study outcomes reported.  
* Two different strains tested are counted as one species. Strains were not always reported. Pathogenic species, in case of an infection model, are not included. 
**The colonization time includes the time from colonization (0 in case of transfer of microbiota to offspring) till and including the time of sacrifice or end of experimental (e.g. dietary) 
manipulations, in case this is clearly stated in the paper. If age is given and animals are colonized at birth, the age is included in colonization time. 
*** Study outcomes are only reported for the animals colonized with the defined community of interest 
Abbreviations: LP = lamina propria; MLN = mesenteric lymph nodes; MPO = myeloperoxidase; NR = not reported; SCFA = short-chain fatty acids; Treg = regulatory T-cell 
Ref. Name consortium (no. of species*) Phylum division Strain 
source 
Host species 
(strain) 
Part of the gut studied No. of 
animals 
per 
group 
Chow Sex 
(M/F, 
both or 
NR) 
Age (col. 
time**) 
Study 
outcomes*** 
 
(33) NA, F- and N-strains (2,9,11,41, 130) 
2: E. coli C25 + Lactobacillus 
9: 2 + enterococcus + Lactobacillus + 
Candida + 4 morphologically different 
strains of gram-negative anaerobes 
11: 9 + 2 strains of gram-negative 
anaerobes with fusiform morphology 
41: 11 + 30 additional strains of gram-
negative anaerobes  
130: 50 strains of gram-negative strict 
anaerobes (N) + 80 facultative 
anaerobes (F) 
 
E. coli C25 + 
Lactobacillus 
 
Others not specified 
Mouse Mouse  
(CD-1) 
 
4-57 Autoclaved 
Lobund diet L-
356 or pelleted 
sterile diet 
from Charles 
River Mouse 
Farms 
NR NR  
(1-60 d) 
Caecal number of E. 
coli C25; caecal 
size; histopathology 
of stomach, small 
intestine, caecum 
and colon 
(34) N- and F-strains (60,96,96,97) 
60: N-strains + 14 facultative 
anaerobes + E. coli C25 
96: F-strains + E. coli C25 or E.coli 40T 
or Shigella  
97: F-strains + E. coli C25 + Shigella or 
E. coli 40T 
 
Not specified Mouse Mouse  
(CD-1) 
 5-75 Sterilized 
Lobound diet L-
356 , Charles 
River Formula 
7RF, Lobound 
diet L-485 or 
Purina Breeder 
Chow 
NR NR  
(4 wk) 
Caecal size; caecal 
levels of fatty acids; 
caecal levels of E. 
coli; pH of caecal 
contents 
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(180) na (4)  
Lactobacillus sp. 1 and 2, Bacteroides 
sp., Streptococcus group N 
  
Rat? Rat (Sprague-
Dawley) 
None 2 Autoclaved 
standard diet 
(Ref 7) 
supplemented 
with caffeic 
acid 
NR NR Urinary metabolites 
of caffeic acids 
(38) na(2,2,2,2,3,3,4,5,6,6,6,8,8,9,13,15,17) 
2: Actinobacillus s3 + Streptococcus s1 
2: Bacteroides s8 + Actinobacillus s3 
2: Eubacterium S10 + Micrococcus s6 
2: Clostridium C1 + C2 
3: Bacteroides s8 + Actinobacillus s3 + 
E. coli s7 
3: Shigella flexneri + C5 + C6 
4: C1-C4 
4: S. flexneri + C3-C5 
6: C1-C6 
6: Actinobacillus s3 + Streptococcus s1 
+ Lactobacillus s4 + Corynebacterium 
s5 + Micrococcus s6 + Streptococcus s2 
6: S. flexneri + C5-C9 
8: 6 (Actinobacillus, etc.) + Bacteroides 
s8 + E. coli s7 
8: S. flexneri + C3-C9 
9: C1-C9, 13: C1-C13, 15: C1-15 
17: 8 (Actinobacillus, etc.) + C1-C9 
(2,2), (2), (2) 
      
 
 
(3), (3) 
(6), (6), (6) 
 
(8), (8) 
 
 
(4,9,13,15), (17) 
 
Human 
and 
mouse  
Mouse  
(CD-1) 
 ≥ 2  Sterilized 
commercial 
diet (Usine 
d'Alimentation 
Rationnelle) ad 
libitum 
Both 2-5 mo  
(4 wk after 
last 
inoculation) 
Number of IgA 
plasmocytes in 
duodenum 
(181) na (2,2,2,2,2,2,2,2,3) 
2,2: Clostridium E or P with E. coli K-12 
2 (x 6): Clostridium E + E. coli S, Proteus 
mirabilis, Klebsiella pneumonia, 
Bacteroides (Alistipes) putredinis, 
Veillonella alcalescens or Clostridium 
perfringens 
(2,2,2,2,2), (2) 
(2,2), (3) 
Mouse, 
rat, 
human 
Mouse 
(C3H) 
 2-6 Autoclaved 
commercial 
diet 
NR Adult (up to 
51 d) 
Faecal bacterial 
counts; (mucosal) 
histology of 
stomach, jejunum, 
ileum, caecum, 
colon 
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3: Clostridium E and P + E. coli K-12 
(37) UW-GL (9) 
Genera Lactobillus, Bacillus, 
Clostridium and Corynebacterium. 
Species not defined.  
UW-GL 
 
NR Mouse  
(Balb/c) 
 Total of 
3 
Sterilized 
Ralson Purina 
5010C 
Both 0  
(60-90 d) 
Caecal levels of 
bacteria and 
Candida albicans; 
histology of tongue 
and stomach 
(108) na (6) 
Streptococcus (Enterococcus) faecalis, 
Lactobacillus brevis, Aerobacter 
aerogenes, Staphylococcus 
epidermidis, Bacteroides spurius (?), a 
yeast fungus 
 NR Mouse 
(Balb/c/ABOMf) 
None 3-6 Sterilized food 
(two different 
procedures) 
NR 0 (14 wk) Serum levels of 
IgG1, IgG2, IgM and 
IgA 
(36) Partial or complete UW-GL (2,3,9) 
2: Lactobacillus + Clostridium 
3: 2 + Bacillus 
9: UW-GL 
 
 
Partial UW-GL 
 
NR and 
mouse 
Mouse 
(HA/ICR) 
 10-48 NR Both Adult  
(14-56 d) 
Death after C. 
botulinum 
infection; faecal C. 
botulinum toxin 
excretion; 
colonization 
pattern of C. 
botulinum 
(109) na (2) 
B. thetaiotaomicron VPI-5482 + 
Desulfovibrio piger ATCC 29098 
 
Human Mouse 
(NMRI/KI) 
 4-5 Autoclaved 
polysaccharide-
rich (B&K) ad 
libitum 
 
M 
(subset) 
Adult or 12 
wk (14-28 
d) 
Bacterial content in 
caecum and distal 
colon; bacterial 
gene expression; 
glycan levels in 
caecum; SCFA 
production in 
caecum; serum 
acetate; liver 
triglycerides; 
epididymal fat pad 
? ? 
? 
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(182) na (2, 6, 10) 
2: Staphylococcus epidermidis + 
Veillonella parvula 
6, 10: anaerobic strains isolated from a 
conventional male mouse (not 
specified) 
(2) Mouse Mouse 
(B10.BR) 
 45-73 Sterilized ST1 
(Institute of 
Physiology AS 
CR) 
M 21 d  
(12 mo) 
Occurrence of 
ankylosing 
enthesopathy of 
the ankle; colon 
histology; bacterial 
content in ileum 
and colon 
(85) na (2) 
B. thetaiotaomicron + Eubacterium 
rectale 
 
Human Mouse  
(NMRI-KI) 
 4-5 Irradiated 
standard low-
fat, plant 
polysaccharide-
rich diet (diet 
2018 from 
Harland Teklad) 
or high-fat, 
"high-sugar" 
Western-type 
diet (Harlan 
Teklad 96132) 
or low-fat, 
"high-sugar" 
(Harland Teklad 
03317) 
M 11 wk (14 
d) 
Bacterial gene 
expression; caecal 
colonization levels; 
fermentation 
efficiency in 
caecum; colonic 
gene expression; 
protein expression 
in caecum 
(39) na (3,8,9,10) 
3: E. coli HS, B. vulgatus DSM1447, B. 
thetaiotaomicron DSM2079 
8: 3 + B. longum NCC2705, Blautia 
hansenii DSM20583, C. scindens 
DSM5676, Eubacterium ventriosum 
DSM3988, Lactobacillus rhamnosus 
NCC4007 
9: 8 + Collinsella aerofaciens DSM3979 
(colonized most mice) 
10: 9 + Faecalibacterium prausnitzii 
DSM17677 (not colonized) 
(3) 
(8), (9), (10) 
 
Human Mouse 
(C3H/HeN) 
 15 in 
total 
Sterile standard 
chow diet or 
switch to high-
fat diet ad 
libitum 
Both 7 wk  
(70 d after 
1st 
inoculation) 
Faecal and caecal 
bacterial cell 
counts; body 
weight; metabolites 
in urine and plasma 
79 
 
(40)  na (15, 19) 
15: Bacteroides caccae, Bacteroides 
ovatus, B. thetaiotaomicron, B. 
uniformis, B. vulgatus, Bacteroides 
WH2, C. scindens, Clostridium 
spiroforme, C. aerofaciens, Dorea 
longicatena, E. rectale, F. prausnitzii, 
Parabacteroides distasonis, 
Ruminococcus obeum, R. torques 
(strain info not accessible) 
19: 15 + Bifidobacterium animalis 
subsp. lactis CNCM I-2494, 
Lactobacillus delbrueckii subsp. 
bulgaricus CNCM I-1632+CNCM I-1519, 
Lactococcus lactis subsp. cremoris 
CNCM I-1631, Streptococcus 
thermophilus CNCM I-1630 
(15) 
(19) 
 
Human Mouse 
(C57Bl/6J) 
 5 Autoclaved low 
fat, plant 
polysaccharide-
rich diet (B&K 
rat and mouse 
autoclavable 
chow 
#7378000) 
M 6-8 wk  
(42 d) 
Faecal and caecal 
bacterial content; 
bacterial gene 
expression; urinary 
metabolites 
(183) na (2) 
B. thetaiotaomicron VPI-5482 (ATCC 
29148) + F. prausnitzii A2-165 (DSM 
17677) 
 
Human Rat (F344) 
 
6-16 Irradiated 
polysaccharide-
rich diet (R03, 
SAFE) 
M < 3 months 
(30 d after 
inoculation 
F. 
prausnitzii) 
Host gene 
expression in 
colonic epithelium; 
SCFA caecal 
concentrations; 
oxidoreduction 
potential in caecal 
contents; colonic 
crypt depth; total 
cells/crypt in colon; 
expression of 
differentiation 
proteins of 
secretory lineage 
(KLF-4, ChgA); 
MUC2 production 
in colonic 
epithelium; colonic 
mucin glycosylation 
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(86) na (2) 
B. thetaiotaomicron VPI-5482 + B. 
longum NCC2705 
  
Human Mouse 
(SW) 
 3 Standard diet 
(Purine LabDiet 
5K67) 
NR NR (10 d) Faecal bacterial 
content; 
metabolites in 
feces and urine 
(42) na (2,8,9) 
2: B. thetaiotaomicron + D. piger 
8: B. thetaiotaomicron, B. caccae, B. 
ovatus, E. rectale, Marvinbryanthia 
formatexigens, C. aerofaciens, E. coli, 
Clostridium symbiosum 
9: 8 + D. piger 
 
(2) 
(8), (9) 
 
Human Mouse (NMRI)  4-20  Irradiated low-
fat/high-plant 
polysaccharides 
or high-
fat/high-simple 
sugars ad 
libitum or the 
HF/HS diet with 
modified 
sulfate 
concentrations 
(600-fold 
range) or 
HF/HS diet 
supplemented 
with 
chondroitin 
sulfate 
M 7-8 wk  
(2 wk) 
Faecal bacterial 
relative abundance; 
faecal 
metatranscriptome; 
gene expression of 
D. piger; gene 
expression of 
mouse proximal 
colon; caecal 
metabolites 
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(45) na (14) + virus-like particles 
C. aerofaciens ATCC 25986, B. caccae 
ATCC 43185, B. ovatus ATCC 8483, B. 
thetaiotaomicron VPI-5482+7330, 
Bacteroides uniformis ATCC 8492, 
Bacteroides vulgatus ATCC 8482, 
Bacteroides cellulosilyticus WH2, 
Parabacteroides distasonis ATCC 8503, 
C. scindens ATCC 35704, C. symbiosum 
ATCC 14940, C. spiroforme DSM 1552, 
D. longicatena DSM 13814, E. rectale 
ATCC 33656, R. obeum ATCC 29174 
 
 
Human Mouse 
(C57BL/6J) 
 5  Autoclaved 
low-fat/high-
plant 
polysaccharide 
diet (B&K) ad 
libitum 
NR 8 wk 
(46 d) 
Gut barrier and 
immune function; 
overall health 
status; body weight 
and adiposity; 
number of CD4+ 
and CD8+ T-cells in 
spleens and MLN; 
faecal bacterial 
content and viral 
abundance; genetic 
changes upon viral 
attack (phage 
resistance); 
bacterial content of 
proximal and distal 
small intestine, 
caecum, colon; 
prophage activation 
(43) No name (14) 
B. ovatus DSM 1896, Bacteroides 
uniformis DSM 8492, B. 
thetaiotaomicron DSM 2079, B. caccae 
DSM 19024, Barnesiella 
intestinihominis YIT11860, Roseburia 
intestinalis 14610, L1-82, E. rectale 
DSM 17629, A1-86, F. prausnitzii DSM 
17677, A2-165, Marvinbryanthia 
formatigenes DSM 14469, I-52, C. 
symbiosum DSM 934, C. aerofaciens 
DSM 3979, E. coli HS, A. muciniphila 
DSM 22959 Muc, D. piger ATC29098 
 
 
Human Mouse (SW) 
 
Total of 
51  
Autoclaved 
standard fiber-
rich (15% 
dietary fiber), 
fiber-free or 
prebiotic 
(addition of 
purified soluble 
glycans) ad 
libitum 
Both 8-9 wk  
(54 d) 
Microbial 
composition in 
feces, caecum, 
colonic lumen and 
mucus layer; 
bacterial CAZyme 
expression in 
caecum; mucin 
specific transcript 
in B. caccae, A. 
muciniphila and 
B.thetaiotaomicron 
caecal microbial 
enzyme activity; 
levels of SCFA and 
organic acids; 
colonic mucus layer 
thickness; colonic 
expression of 
82 
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mucus-production 
related genes; 
number of goblet 
cells in colon; 
histopathology; 
body weight; faecal 
lipocalin; colon 
length; caecal 
transcriptome; 
after infection with 
C. rodentium: 
histological score of 
caecum and colon, 
area of inflamed 
tissue in caecum, 
survival, ascending 
and descending 
colon and rectum, 
adherent C. 
rodentium in colon 
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Table 1c. Studies using defined communities to study host-microbe interactions in vivo: Communities in non-rodents (n = 6) 
The following study characteristics are listed: microbial consortium name (if applicable), taxonomic affiliation, strain source, host species and strain, part of the gut studied, no. of animals per 
experimental group, diet, sex, age and study outcomes reported.  
* Two different strains tested are counted as one species. Strains were not always reported. Pathogenic species, in case of an infection model, are not included. 
**The colonization time includes the time from colonization (0 in case of transfer of microbiota to offspring) till and including the time of sacrifice or end of experimental (e.g. dietary) 
manipulations, in case this is clearly stated in the paper. If age is given and animals are colonized at birth, the age is included in colonization time. 
*** Study outcomes are only reported for the animals colonized with the defined community of interest 
Abbreviations: LP = lamina propria; MLN = mesenteric lymph nodes; MPO = myeloperoxidase; NR = not reported; SCFA = short-chain fatty acids; Treg = regulatory T-cell 
Ref. Name consortium (no. of species*) Phylum division Strain 
source 
Host 
species 
(strain) 
Part of the gut studied No. 
of 
anim
als 
per 
grou
p 
Chow Sex 
(M/F
, 
both 
or 
NR) 
Age 
(col. 
time**
) 
Study outcomes*** 
 
(52) Bristol (3,4), Modified ASF (6,7,7) 
3: Lactobacillus amylovorus DSM 
16698T, Clostridium glycolicum and 
Parabacteroides sp. (ASF519)  
4: 3 + R. intestinalis 
6: Clostridium sp. (ASF356), 
Lactobacillus sp. (ASF360), Lactobacillus 
animalis (ASF361), E. plexicaudatum 
(ASF492), Parabacteroides sp. (ASF519) 
and Propionibacterium sp.  
7: 6 + Staphylococcus sp. or Bacillus sp.  
Bristol (3), (4)  
Mod.ASF (6), (7,7) 
 
 
Pig Pig 
(commercia
l hybrid and 
Babraham) 
 2-6 Evaporated 
milk 
NR 0-17 d  
(14-21 
d after 
1st 
inocula
tion) 
Presence of bacteria and mean 
total bacterial content in 
proximal and distal jejunum, 
terminal ileum, caecum and 
colon; serum immunoglobulin 
concentrations 
(59) Bristol (3) Pig Pig ((Great 
York x Pie) 
x 'Dalland' 
cross) 
 6 Pasteurized 
sow 
colostrum 
(first hrs), an 
ad libitum 
milk replacer 
diet, (day 0-
4), a moist 
diet 
(remaining) 
NR Neonat
es (26-
37 d) 
Relative OR51E1 expression in 
jejunum 
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(60) Bristol (3) Pig Pig ((Great 
York x 
Pietrain) x 
'Dalland' 
cross 
 6 Sow serum or 
pasteurized 
sow 
colostrum, 
followed by 
ad libitum 
milk replacer 
diet (day 0-4), 
followed by a 
control diet 
or medium 
chain fatty 
acid diet 
NR 1 d  
(2-3 
wk) 
Oxyntic mucosa transcriptome 
(62) DMF (7,8) 
Bifidobacterium adolescentis, B. 
longum, B. thetaiotaomicron, E. 
faecalis, L. brevis, S. bovis and C. 
clostridioforme 
8: DMF + E. coli Nissle 
 
DMF 
 
(8) 
Pig Pig 
(Landrace × 
Yorkshire × 
Duroc 
cross-bred) 
 3-6 NR NR 7 d  
(35 d) 
Faecal virus shedding; mean 
duration of diarrhea; diarrhea 
severity and percentage of 
diarrhea; gene expression 
levels of CgA, MUC2, PCNA, 
SOX9 and villin in jejunal 
intestinal epithelial cells 
(63) Pig Pig (NR)  3-5 NR NR 5 d  
(14-35 
d) 
Bacterial content in rectum, 
duodenum, jejunum, ileum, 
colon and feces/rectal swabs; 
diarrhoea and virus shedding 
after virulent human rotavirus 
challenge 
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Table 2. Advantages and pitfalls of gnotobiotic animal models in comparison with human research, with 
respect to the factors influencing intestinal microbiota composition or behaviour. Based on studies listed in 
Table 1a-c and literature. 
Factor Advantage (vs. human research) Pitfalls in practice 
Inoculum 
(defined 
community) 
• Controllable composition 
Healthy vs. diseased microbiota 
(e.g. missing key stone species), 
human- vs. animal-derived 
• Animal microbiome ≠ human microbiome 
• Difficulties in defining a healthy or normal 
microbiota 
• Host-specific selection of microbiota 
Diet • Controllable composition, 
timing, amount 
Tailored to human diet (region, 
age, season, etc.) 
• Lack of standardization in lab animal feeding 
protocols 
• Not always reported (Table 1a-c) 
 
Host genotype • Controllable – genetic 
changes possible 
Ability to introduce disease 
• Validation of HMIs in multiple strains needed 
before extrapolation to humans 
• Animal genotype ≠ human genotype 
Sex • Controllable • Only one gender investigated (Table 1a-c) 
• Not always reported (Table 1a-c) 
Part of the gut •  Ability to measure bacterial 
levels in virtually all 
intestinal parts 
• Ability to capture 
transversal heterogeneity 
• Anatomy and physiology different from 
humans 
• Variations in relative abundance per gut 
region different per model (Table 1a-c) 
• Focus on specific gut regions or faeces only 
(Table 1a-c) 
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Colonization 
time 
• Controllable • Long-term effects not studied (Table 1a-c) 
• Animals not always colonized starting at birth 
(Table 1a-c)  
• Stability over generations not always 
confirmed (Table 1a-c) 
Immune 
system 
• Controllable at start/birth • Uncontrollable in long-term studies, 
especially locally 
• Complex, determined by in- and external 
factors 
• Not quantified or quantifiable (Table 1a-c) 
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